234 Church Street
About Biohaven Pharma
235 articles with Biohaven Pharma
Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy
Biohaven Ltd. (NYSE: BHVN; "Biohaven") announced today that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for taldefgrobep alfa, a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (SMA).
Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference
Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California, on Tuesday, January 10, 2023 at 7:30 am (PT).
Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University
Biohaven Ltd. announced advancements in the development of its MoDE extracellular target degrader platform technology licensed from Yale University for various disease indications, including, but not limited to, neurological disorders, cancer, infectious and autoimmune diseases.
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Biohaven Ltd. (NYSE: BHVN) (the "Company" or "Biohaven") today announced the closing of an underwritten public offering of 28,750,000 of its common shares, which includes the full exercise of the underwriters' option to purchase 3,750,000 additional shares, at the public offering price of $10.50 per share.
Biohaven Announces Pricing of Public Offering of Common Shares - October 21, 2022
Biohaven Ltd. announced the pricing of the public offering of 25,000,000 of its common shares, at a public offering price of $10.50 per common share.
Biohaven will focus on developing therapeutics that modulate the Kv7 Ion Channel for the treatment of neurological and neuropsychiatric diseases. The new entity launched with $257.8 million in cash.
Pfizer Completes Acquisition of Biohaven Pharmaceuticals
Pfizer Inc. announced the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT, an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.
Clene’s gold nanocrystal asset CNM-Au8 failed to hit the primary endpoint in the HEALEY ALS trial, but strong survival signals at six months warrant additional exploration in treating ALS.
Biohaven Provides Update From Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial)
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced results from a focused analysis of treatment with verdiperstat in the HEALEY ALS Platform Trial in amyotrophic lateral sclerosis (ALS).
Biohaven Pharma's verdiperstat, an experimental treatment for amyotrophic lateral sclerosis, failed to distinguish itself from placebo in clinical testing, the company announced Thursday.
Biohaven Announces Record Date for Anticipated Spin-Off
Biohaven Pharmaceutical Holding Company Ltd. announced that it has set a record date of September 26, 2022 for the previously announced spin-off by Biohaven of its Biohaven Ltd. subsidiary, which will own the Kv7 ion channel activators, glutamate modulation, myeloperoxidase inhibition and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure currently owned by Biohaven.
Real-World Administrative Claims Analysis Demonstrates That Almost Half of Migraine Patients Discontinue Barbiturate Use After Initiation of Nurtec ODT
Biohaven Pharmaceutical Holding Company Ltd. announced the important findings pertaining to the benefit of Nurtec® ODT in decreasing the burden of butalbital use among migraine patients in real world clinical practice.
Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for the second quarter ended June 30, 2022, and provided a review of recent accomplishments during and anticipated upcoming milestones.
Intercept Pharmaceuticals, Annovis Bio and Biohaven Pharma are moving forward with late-stage Phase III clinical trials.
Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)
Biohaven Pharmaceutical Holding Company Ltd. today announced that it has commenced enrollment in a Phase 3 clinical trial assessing the efficacy and safety of taldefgrobep alfa in Spinal Muscle Atrophy (SMA).
A new report by PwC projects that the second half of this year will see a “flurry of deals activity across all areas of the sector.”
Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society
Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society.
It was an extraordinarily busy week for clinical trial news and updates due to several prominent international conferences. Here’s a look at some of the highlights.
Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific Meeting of the American Headache Society
31 new and encore presentations, including three late-breakers and three oral presentations, spotlight robust Nurtec ODT, zavegepant and migraine HEOR data.
The annual meeting of the American Headache Society (AHS) is being held in Denver, Colorado from June 9-12. Here’s a look at just some of the wide-ranging research being presented.